News
Clinical Trials Arena on MSN6d
Vividion begins subject dosing in trial of RAS-driven cancer treatmentThe therapy is the fourth clinical-stage programme derived from the company’s chemoproteomics discovery platform.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback